Is Ercros (BME:ECR) A Future Multi-bagger?

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key financial metrics. Firstly, we'll want to see a proven return on capital employed (ROCE) that is increasing, and secondly, an expanding base of capital employed. If you see this, it typically means it's a company with a great business model and plenty of profitable reinvestment opportunities. So when we looked at Ercros (BME:ECR) and its trend of ROCE, we really liked what we saw.

Advertisement

Understanding Return On Capital Employed (ROCE)

For those that aren't sure what ROCE is, it measures the amount of pre-tax profits a company can generate from the capital employed in its business. Analysts use this formula to calculate it for Ercros:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)

0.026 = €10m ÷ (€525m - €117m) (Based on the trailing twelve months to September 2020).

Thus, Ercros has an ROCE of 2.6%. Ultimately, that's a low return and it under-performs the Chemicals industry average of 9.7%.

View our latest analysis for Ercros

roce
BME:ECR Return on Capital Employed February 22nd 2021

In the above chart we have measured Ercros' prior ROCE against its prior performance, but the future is arguably more important. If you're interested, you can view the analysts predictions in our free report on analyst forecasts for the company.

The Trend Of ROCE

Even though ROCE is still low in absolute terms, it's good to see it's heading in the right direction. Over the last five years, returns on capital employed have risen substantially to 2.6%. Basically the business is earning more per dollar of capital invested and in addition to that, 61% more capital is being employed now too. This can indicate that there's plenty of opportunities to invest capital internally and at ever higher rates, a combination that's common among multi-baggers.

One more thing to note, Ercros has decreased current liabilities to 22% of total assets over this period, which effectively reduces the amount of funding from suppliers or short-term creditors. So shareholders would be pleased that the growth in returns has mostly come from underlying business performance.

The Bottom Line

To sum it up, Ercros has proven it can reinvest in the business and generate higher returns on that capital employed, which is terrific. And a remarkable 387% total return over the last five years tells us that investors are expecting more good things to come in the future. In light of that, we think it's worth looking further into this stock because if Ercros can keep these trends up, it could have a bright future ahead.

Like most companies, Ercros does come with some risks, and we've found 2 warning signs that you should be aware of.

For those who like to invest in solid companies, check out this free list of companies with solid balance sheets and high returns on equity.

If you decide to trade Ercros, use the lowest-cost* platform that is rated #1 Overall by Barron’s, Interactive Brokers. Trade stocks, options, futures, forex, bonds and funds on 135 markets, all from a single integrated account. Promoted


Valuation is complex, but we're here to simplify it.

Discover if Ercros might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020


Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

About BME:ECR

Ercros

Manufactures and sells basic chemicals, intermediate chemicals, and pharmaceuticals in Spain.

Reasonable growth potential and fair value.

Advertisement

Weekly Picks

TA
Talos
TSLA logo
Talos on Tesla ·

The "Physical AI" Monopoly – A New Industrial Revolution

Fair Value:US$665.3635.6% undervalued
25 users have followed this narrative
14 users have commented on this narrative
16 users have liked this narrative
MA
CSG logo
Marek_Trnka on CSG ·

Czechoslovak Group - is it really so hot?

Fair Value:€5547.0% undervalued
34 users have followed this narrative
1 users have commented on this narrative
13 users have liked this narrative
AL
alex30free
SECARE logo
alex30free on Swedencare ·

The Compound Effect: From Acquisition to Integration

Fair Value:SEK 46.2846.5% undervalued
9 users have followed this narrative
0 users have commented on this narrative
1 users have liked this narrative

Updated Narratives

DM
DMXS
EEE logo
DMXS on Coca-Cola HBC ·

A Tale of Two Engines: Coca-Cola HBC (EEE.AT)

Fair Value:€576.1% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
CO
composite32
TTE logo
composite32 on TotalEnergies ·

This strategic transformation of TTE? Significant re-rating potential

Fair Value:€68.56.1% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
MA
MarkoVT
5253 logo
MarkoVT on COVER ·

Q3 Outlook modestly optimistic

Fair Value:JP¥1.58k2.1% undervalued
10 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

OO
NEO logo
OOO97 on Neo Performance Materials ·

Undervalued Key Player in Magnets/Rare Earth

Fair Value:CA$25.3317.2% undervalued
78 users have followed this narrative
0 users have commented on this narrative
20 users have liked this narrative
DA
davidlsander
UBI logo
davidlsander on Ubisoft Entertainment ·

Is Ubisoft the Market’s Biggest Pricing Error? Why Forensic Value Points to €33 Per Share

Fair Value:€33.887.8% undervalued
57 users have followed this narrative
5 users have commented on this narrative
25 users have liked this narrative
AN
AnalystConsensusTarget
MSFT logo
AnalystConsensusTarget on Microsoft ·

Analyst Commentary Highlights Microsoft AI Momentum and Upward Valuation Amid Growth and Competitive Risks

Fair Value:US$603.2233.0% undervalued
1267 users have followed this narrative
2 users have commented on this narrative
9 users have liked this narrative

Trending Discussion

Advertisement